- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- homo-hexamer
- Ligands
- 12 x LMN: Lauryl Maltose Neopentyl Glycol(Non-covalent)
- 6 x P5S: O-[(R)-{[(2R)-2,3-bis(octadecanoyloxy)propyl]oxy}(hydroxy)phosphoryl]-L-serine(Non-covalent)
P5S.2: 10 residues within 4Å:- Chain A: G.224, L.228, Y.231, F.232, L.281, Y.285, W.288, G.302, I.334
- Ligands: CDL.5
6 PLIP interactions:6 interactions with chain A- Hydrophobic interactions: A:L.228, A:L.281, A:Y.285, A:W.288, A:W.288, A:I.334
P5S.8: 10 residues within 4Å:- Chain B: G.224, L.228, Y.231, F.232, L.281, Y.285, W.288, G.302, I.334
- Ligands: CDL.9
6 PLIP interactions:6 interactions with chain B- Hydrophobic interactions: B:L.228, B:L.281, B:Y.285, B:W.288, B:W.288, B:I.334
P5S.12: 10 residues within 4Å:- Chain C: G.224, L.228, Y.231, F.232, L.281, Y.285, W.288, G.302, I.334
- Ligands: CDL.13
6 PLIP interactions:6 interactions with chain C- Hydrophobic interactions: C:L.228, C:L.281, C:Y.285, C:W.288, C:W.288, C:I.334
P5S.16: 10 residues within 4Å:- Chain D: G.224, L.228, Y.231, F.232, L.281, Y.285, W.288, G.302, I.334
- Ligands: CDL.17
6 PLIP interactions:6 interactions with chain D- Hydrophobic interactions: D:L.228, D:L.281, D:Y.285, D:W.288, D:W.288, D:I.334
P5S.20: 10 residues within 4Å:- Chain E: G.224, L.228, Y.231, F.232, L.281, Y.285, W.288, G.302, I.334
- Ligands: CDL.21
6 PLIP interactions:6 interactions with chain E- Hydrophobic interactions: E:L.228, E:L.281, E:Y.285, E:W.288, E:W.288, E:I.334
P5S.24: 10 residues within 4Å:- Chain F: G.224, L.228, Y.231, F.232, L.281, Y.285, W.288, G.302, I.334
- Ligands: CDL.3
6 PLIP interactions:6 interactions with chain F- Hydrophobic interactions: F:L.228, F:L.281, F:Y.285, F:W.288, F:W.288, F:I.334
- 6 x CDL: CARDIOLIPIN(Non-covalent)
CDL.3: 17 residues within 4Å:- Chain A: F.109, I.146, A.150, G.153, A.154, I.157, P.158, S.161, A.165
- Chain F: L.47, V.51, A.54, F.328, T.330, L.336, V.337
- Ligands: P5S.24
13 PLIP interactions:6 interactions with chain F, 7 interactions with chain A- Hydrophobic interactions: F:L.47, F:L.47, F:V.51, F:F.328, F:L.336, F:V.337, A:F.109, A:I.146, A:A.150, A:I.157, A:A.165
- Hydrogen bonds: A:S.161, A:S.161
CDL.5: 18 residues within 4Å:- Chain A: L.47, V.51, A.54, F.328, T.330, L.336, V.337
- Chain B: F.109, I.146, A.150, G.153, A.154, I.157, P.158, D.159, S.161, A.165
- Ligands: P5S.2
13 PLIP interactions:7 interactions with chain B, 6 interactions with chain A- Hydrophobic interactions: B:F.109, B:I.146, B:A.150, B:I.157, B:A.165, A:L.47, A:L.47, A:V.51, A:F.328, A:L.336, A:V.337
- Hydrogen bonds: B:S.161, B:S.161
CDL.9: 17 residues within 4Å:- Chain B: L.47, V.51, A.54, F.328, T.330, L.336, V.337
- Chain C: F.109, I.146, A.150, G.153, A.154, I.157, P.158, S.161, A.165
- Ligands: P5S.8
13 PLIP interactions:6 interactions with chain B, 7 interactions with chain C- Hydrophobic interactions: B:L.47, B:L.47, B:V.51, B:F.328, B:L.336, B:V.337, C:F.109, C:I.146, C:A.150, C:I.157, C:A.165
- Hydrogen bonds: C:S.161, C:S.161
CDL.13: 17 residues within 4Å:- Chain C: L.47, V.51, A.54, F.328, T.330, L.336, V.337
- Chain D: F.109, I.146, A.150, G.153, A.154, I.157, P.158, S.161, A.165
- Ligands: P5S.12
13 PLIP interactions:7 interactions with chain D, 6 interactions with chain C- Hydrophobic interactions: D:F.109, D:I.146, D:A.150, D:I.157, D:A.165, C:L.47, C:L.47, C:V.51, C:F.328, C:L.336, C:V.337
- Hydrogen bonds: D:S.161, D:S.161
CDL.17: 17 residues within 4Å:- Chain D: L.47, V.51, A.54, F.328, T.330, L.336, V.337
- Chain E: F.109, I.146, A.150, G.153, A.154, I.157, P.158, S.161, A.165
- Ligands: P5S.16
13 PLIP interactions:6 interactions with chain D, 7 interactions with chain E- Hydrophobic interactions: D:L.47, D:L.47, D:V.51, D:F.328, D:L.336, D:V.337, E:F.109, E:I.146, E:A.150, E:I.157, E:A.165
- Hydrogen bonds: E:S.161, E:S.161
CDL.21: 17 residues within 4Å:- Chain E: L.47, V.51, A.54, F.328, T.330, L.336, V.337
- Chain F: F.109, I.146, A.150, G.153, A.154, I.157, P.158, S.161, A.165
- Ligands: P5S.20
13 PLIP interactions:7 interactions with chain F, 6 interactions with chain E- Hydrophobic interactions: F:F.109, F:I.146, F:A.150, F:I.157, F:A.165, E:L.47, E:L.47, E:V.51, E:F.328, E:L.336, E:V.337
- Hydrogen bonds: F:S.161, F:S.161
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Pye, V.E. et al., A bipartite structural organization defines the SERINC family of HIV-1 restriction factors. Nat.Struct.Mol.Biol. (2020)
- Release Date
- 2020-01-01
- Peptides
- Membrane protein TMS1d: ABCDEF
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DE
EF
F - Membrane
-
We predict this structure to be a membrane protein.
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- homo-hexamer
- Ligands
- 12 x LMN: Lauryl Maltose Neopentyl Glycol(Non-covalent)
- 6 x P5S: O-[(R)-{[(2R)-2,3-bis(octadecanoyloxy)propyl]oxy}(hydroxy)phosphoryl]-L-serine(Non-covalent)
- 6 x CDL: CARDIOLIPIN(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Pye, V.E. et al., A bipartite structural organization defines the SERINC family of HIV-1 restriction factors. Nat.Struct.Mol.Biol. (2020)
- Release Date
- 2020-01-01
- Peptides
- Membrane protein TMS1d: ABCDEF
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DE
EF
F - Membrane
-
We predict this structure to be a membrane protein.